Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135 USD | +1.43% | -0.32% | +2.44% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 58% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 33.26 and 21.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.44% | 13.58B | C+ | ||
+18.72% | 125B | B+ | ||
+14.19% | 108B | B+ | ||
-4.93% | 24.21B | B+ | ||
+0.73% | 22.78B | B | ||
-10.58% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.31% | 16.37B | B | ||
+27.89% | 11.66B | C+ | ||
+83.45% | 9.17B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- Ratings Neurocrine Biosciences, Inc.